Aytu Bioscience (NASDAQ:AYTU) and Urovant Sciences (NASDAQ:UROV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.
This table compares Aytu Bioscience and Urovant Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings for Aytu Bioscience and Urovant Sciences, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aytu Bioscience currently has a consensus price target of $4.88, indicating a potential upside of 550.00%. Urovant Sciences has a consensus price target of $25.33, indicating a potential upside of 147.15%. Given Aytu Bioscience’s higher probable upside, equities research analysts plainly believe Aytu Bioscience is more favorable than Urovant Sciences.
Risk and Volatility
Aytu Bioscience has a beta of 4.63, meaning that its stock price is 363% more volatile than the S&P 500. Comparatively, Urovant Sciences has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500.
Institutional and Insider Ownership
15.7% of Aytu Bioscience shares are held by institutional investors. Comparatively, 24.3% of Urovant Sciences shares are held by institutional investors. 5.8% of Aytu Bioscience shares are held by company insiders. Comparatively, 2.4% of Urovant Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Aytu Bioscience and Urovant Sciences’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aytu Bioscience||$7.32 million||2.12||-$27.13 million||($3.48)||-0.22|
|Urovant Sciences||N/A||N/A||-$111.35 million||($4.43)||-2.31|
Aytu Bioscience has higher revenue and earnings than Urovant Sciences. Urovant Sciences is trading at a lower price-to-earnings ratio than Aytu Bioscience, indicating that it is currently the more affordable of the two stocks.
Aytu Bioscience beats Urovant Sciences on 8 of the 12 factors compared between the two stocks.
Aytu Bioscience Company Profile
Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia. It also offers MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. In addition, the company provides MiOXSYS analyzer, a portable lightweight desktop platform that is used in clinical or research laboratory or near a patient care area; and MiOXSYS disposable sensors. The company is based in Englewood, Colorado.
Urovant Sciences Company Profile
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Receive News & Ratings for Aytu Bioscience Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aytu Bioscience and related companies with MarketBeat.com’s FREE daily email newsletter.